Adolor to begin Phase III of opioid bowel dysfunction drug
This article was originally published in Scrip
Executive Summary
Adolor is planning Phase III trials of its opioid bowel dysfunction candidate, ADL5945, after reporting positive top-line results from two Phase II trials of the drug in chronic non-cancer pain patients with opioid-induced constipation (OIC).